Below are the key highlights from yesterday's CMD. We remind that Heineken announced EverGreen 2030 financial ambitions including a mid single digit organic net revenue growth with operating profit (beia) growing ahead, ao supported by € 400-500m annual gross savings. We believe these ambitions are not materially different from the EverGreen 2025 targets (4-8% operating profit beia growth) and are also incorporated in our forecasts, which bank on a net revenue CAGR of about 4% and an operating p...
Alfen: Preview - kitchen sinking again? CM.com: New CFO appointed. Cofinimmo: Good results a touch better than forecasts, guidance reconfirmed, DEME Group: Wins strategic position in Brazil. D'Ieteren: State Farm TPA contract details emerge. Signify: 3Q25 results – guidance cut. Xior Student Housing: 5.4% LFL growth and full occupancy – operational trends solid.
Onward announced the placement of 11.3m new ordinary shares in a private placement by way of an accelerated bookbuild offering at an issue price of € 4.5 per share (approx. 12.5% discount to closing price prior to deal announcement) resulting in gross proceeds of € 50.85m. Onwards cash runway is extended through at least end of 2026 (previously 1H26), assuming no drawdown of the company's debt facility with Runway Growth. The transaction was supported by existing and new, long-only and sector sp...
Cofinimmo reports higher than expected EPRA earnings on the back of lower interest charges and lower taxes. 75% of the EUR 100.0m divestment plan is completed and only EUR 66.0m investments, out of the EUR 170.0m guided. Despite Cofinimmo reporting EPRA results far ahead of its minimum EUR 6.20 guided, it does not increase its guidance. Important to note, is that the one-off costs related to the Aedifica merger (approx. EUR 3.0m in 3Q25 in other expenses) and the divestment of financial lease re...
Xior reported EPRA EPS of €1.52 that came slightly below our €1.53 expectation (excl. IFRIC costs). However, Xior confirmed its flat EPRA EPS outlook for FY25 of 2.21 per share. The new rental season in Iberia and Poland starts mainly in 4th quarter. Xior NRI rose 7% yoy and like-for-like growth remained strong at 5.42%. LTV% continued below 50% at 49.75%. The cost of debt decreased slightly from 3.10% (FY24) to 3.06%. The asset disposal program has largely terminated and Xior gradually develops...
ONWARD Medical Successfully Raises Over EUR 50 Million in Capital Increase NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE. THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) Successful transaction supported by strong demand from existing and new high-quality, lon...
Galapagos to Present In Vitro Data at ACR Convergence 2025 Suggesting Differentiation of GLPG3667 from Other TYK2 Inhibitors Mechelen, Belgium; October 23, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present new in vitro pharmacological data from its selective TYK2 inhibitor, GLPG3667, currently in two Phase 3-enabling studies in dermatomyositis (DM) and systemic lupus erythematosus (SLE), at the American College of Rheumatology (ACR) Convergence 2025, taking place in Chicago, IL, October 24-29, 2025. The data show that the in vitro pharmacological ...
Galapagos presenteert in vitro-gegevens tijdens ACR Convergence 2025 die wijzen op differentiatie van GLPG3667 ten opzichte van andere TYK2-remmers Mechelen, België; 23 oktober 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) heeft vandaag aangekondigd dat het nieuwe in vitro farmacologische gegevens zal presenteren van zijn selectieve TYK2-remmer, GLPG3667, die momenteel in twee fase 3-bepalende studies wordt onderzocht bij dermatomyositis (DM) en systemische lupus erythematodes (SLE), op het American College of Rheumatology (ACR) Convergence 2025, dat plaatsvindt in Chicago, Illino...
DEME wins auction for Port of Paranaguá access channel concession in Brazil DEME yesterday won Brazil’s first-ever auction for a port access channel concession. The Canal Galheta Dredging Consortium (CCGD), formed by DEME and FTS Participações Societárias S.A. (FTS), secured a 25-year concession contract to operate, maintain, and expand the marine access channel to the Port of Paranaguá - Brazil’s second-largest public port in the state of Paraná. Attachment
DEME wint veiling voor concessie toegangskanaal van Haven van Paranaguá in Brazilië DEME heeft gisteren de allereerste Braziliaanse veiling voor een concessie van een haventoegangskanaal gewonnen. Het Canal Galheta Dredging Consortium (CCGD), gevormd door DEME en FTS Participações Societárias S.A. (FTS), heeft een 25-jarig concessiecontract binnengehaald voor de exploitatie, onderhoud en uitbreiding van het maritieme toegangskanaal tot de Haven van Paranaguá – de op één na grootste openbare haven van Brazilië, gelegen in de deelstaat Paraná. Bijlage ...
Aalberts: 3Q in line, FY margin now low end of guidance. Acomo: Going from strength to strength. Ahold Delhaize: New $860m distribution centre for Food Lion. Azelis: Weak 3Q25 as broadly expected, CFO to step down. Barco: Press release ahead of CMD. BE Semiconductor Industries: 3Q25 Results – Delivered on order intake. Econocom: 3Q25 organic growth down to c.3.4%, full year growth guidance confirmed. Heineken: EverGreen 2030. Kinepolis: Weak 3Q25 as expected, with Netherlands at ...
Heineken's EverGreen 2030 financial ambitions that will be presented further at today's CMD include a mid single digit organic net revenue growth with operating profit (beia) growing ahead, ao supported by € 400-500m annual gross savings. We believe these ambitions are not materially different from the EverGreen 2025 targets (4-8% operating profit beia growth) and are also incorporated in our forecasts. We still appreciate Heineken for the organic earnings growth potential, supported by ongoing ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.